Extra Hep B Vaccine Dose Exceeds Expectations for People With HIV
WASHINGTON — Three doses of hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG; Heplisav-B) notched a perfect mark when it came to seroprotection for people with HIV who had never before been vaccinated against the hepatitis B virus (HBV), early results of a phase III trial showed. At 28 weeks, the three doses yielded […]